teriflunomide accord
accord healthcare s.l.u. - teriflunomide - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok, szelektív immunszuppresszánsok - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
teriflunomide pharmascience 14 mg filmtabletta
pharmascience international ltd. - teriflunomide -
teriflunomide msn 14 mg filmtabletta
msn labs europe limited - teriflunomide -
teriflunomide win medica 14 mg filmtabletta
win medica s.a. - teriflunomide -
teriflunomide teva 14 mg filmtabletta
teva b.v. - teriflunomide -
tysabri
biogen netherlands b.v. - natalizumabot - szklerózis multiplex - szelektív immunszuppresszánsok - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tyruko
sandoz gmbh - natalizumabot - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
fampridine accord
accord healthcare s.l.u. - fampridine - szklerózis multiplex - egyéb idegrendszeri gyógyszerek - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).
dimetil-fumarát stada 120 mg gyomornedv-ellenálló kemény kapszula
stada arzneimittel ag - dimetil-fumarát -
dimetil-fumarát stada 240 mg gyomornedv-ellenálló kemény kapszula
stada arzneimittel ag - dimetil-fumarát -